Despite the equivocal reports in the mainstream media of the recently released omega-3s trials, the huge statistical power of the studies means the promising secondary endpoints can be trusted, experts say.
Krill-derived omega-3 fatty acids appear to reduce fasting levels of blood glucose, a Rimfrost-funded study finds, as researchers point to its supplementation as an effective approach in reducing cardiovascular disease (CVD) risk.
Amarin Corporation, maker of EPA drug Vascepa, has sued two omega-3s finished good manufacturers for unfair trade practices for allegedly using the results of the company’s large scale drug trial to market their own fish-oil based dietary supplements.
You’ve heard of EPA and DHA omega-3, but what about ETA? A new study from Canada indicates that ETA (eicosatetraenoic acid, 20:4) may convert into two novel compounds associated with inflammation management.
A population study conducted on a cohort living in Boston has found an association of higher blood levels of omega-3s with better executive function in older individuals. The researchers also found negative connotations with higher omega-6 levels.
A review conducted by researchers in New York uncovered six potential modes of action for how omega-3s might alleviate symptoms of anxiety. But the researchers found lots of nits to pick with the research, too, and made recommendations for future studies...
Results from an omega-3 study found a positive link between treatment using EPA and cardiovascular outcomes. It was backed by pharmaceutical company Amarin, which enjoyed a 300% surge in shares after the study results were announced.